CREON Dosing Guide

Determine your patient’s dose

The dosing guide calculates an appropriate dose or dosing range for each patient based on guidelines established by the Cystic Fibrosis Foundation (CFF).1

CREON
Per-meal Dosing Guide

CREON is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

Select your patient’s

ASSOCIATED CONDITION

Select your patient's

AGE

Select your patient's

WEIGHT

  • Select One

    Rx Script Example

    ePrescribing Reminder

    Rx Script Example

    CREON (pancrelipase)

    Lipase Units/120 mL

    of formula or per breast-feeding

    30-day total:

    To calculate dispense quantity for 30 days, multiply the max number of feedings given per day x 30 days.

    This is intended for informational use only and shows the minimum appropriate recommended dosing for the patient criteria specified. The total daily dose should not exceed 10,000 lipase units/kg body weight/day unless clinically indicated. CREON dosage should be individualized and adjusted based on the clinical symptoms, degree of steatorrhea present, and the fat content of the diet.

    ePrescribing Reminder

    When using e-prescribing systems, please make sure to specify the number of capsules that should be taken per meal and per snack in the notes area.

    Example notes:

     Lipase Units/120 mL of formula or per breast-feeding.

    To calculate dispense quantity for 30 days, multiply the max number of feedings given per day x 30 days.

    Email Recommended Dose

     

    CREON should be taken during every meal and snack1

    sample dinner and snack to take CREON with sample dinner and snack to take CREON with

    Meals and snacks are for illustrative purposes only.

    Safety and dosing considerations

    • CREON should be initiated at the lowest recommended dose based on the patient’s weight.
    • CREON should always be taken with food. CREON should not be crushed or chewed.
    • Usually, half of the prescribed CREON dose for an individualized full meal should be given with each snack.
    • Total daily dose should not exceed 10,000 lipase units/kg body weight/day unless clinically indicated.*
    • Fibrosing colonopathy has been reported in patients with cystic fibrosis taking high-dose pancreatic enzyme replacement therapy.

    *The CFF Guidelines also provide a dietary fat-based maximum lipase dose of less than 4,000 units per g of fat ingested per day.

    Use the CREON® (pancrelipase) Treatment Tracker to help educate patients about their therapy

    Encourage patients to track treatment and share the results with you

    Download
    Treatment Tracker
    CREON® (pancrelipase) support programs offer nutritional, educational and financial assistance

    CREON patient support programs offer financial, multivitamin, and educational support

    See Patient Support
    Programs
    Request patient starter kits, product samples, and more

    Request patient starter kits, product samples, and more

    Contact a Rep

    Indications and Important
    Safety Information

    Indications1

    CREON® (pancrelipase) Delayed-Release Capsules is a pancrelipase which is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.

    Important Safety Information

    • Fibrosing colonopathy is associated with high-dose use of pancreatic enzyme replacement in the treatment
      of cystic fibrosis patients. Exercise caution when doses of CREON exceed 2,500 lipase units/kg of body weight
      per meal (or greater than 10,000 lipase units/kg of body weight per day).
    • To avoid irritation of oral mucosa, care should be taken to ensure that CREON is not crushed, chewed, or retained in the mouth. CREON should always be taken with food.
    • Porcine-derived pancreatic enzyme products contain purines. Caution should be exercised when prescribing CREON to patients with gout, renal impairment, or hyperuricemia.
    • There is theoretical risk of viral transmission with all pancreatic enzyme products including CREON.
    • Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.
    • Adverse reactions that occurred in at least 2 cystic fibrosis patients (greater than or equal to 4%) receiving CREON were vomiting, dizziness, and cough.
    • Adverse reactions that occurred in at least 1 chronic pancreatitis or pancreatectomy patient (greater than or equal to 4%) receiving CREON were hyperglycemia, hypoglycemia, abdominal pain, abnormal feces, flatulence, frequent bowel movements, and nasopharyngitis.
    • CREON is not interchangeable with any other pancrelipase product.

    Reference: 1. CREON [package insert]. North Chicago, IL: AbbVie Inc.

    1. Reference:
    2. CREON [package insert]. North Chicago, IL: AbbVie Inc.

    back to top #tbd